Project Grant R01AR086381
Award Date 9/5/25
Completion Date 6/30/30
Dollars Obligated $647K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting the development of an intraarticular (injectable) Wnt inhibitor therapy for the treatment of osteoarthritis (OA). OA is a common and debilitating joint disease affecting nearly 21 million people in the U.S. The $314,363 award, made on September 16, 2025, will fund the...
- This federal Project Grant award of $1,950,412.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), to Wake Forest University Health Sciences. The funding supports research to define how the IRE1A-XBP1-NUPR1 signaling axis in immune cells and chondrocytes contributes to synovial inflammation, cartilage damage, and osteoarthritis pain. The...
- This Project Grant award, valued at $196,460.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The purpose of the award is to test a miniature knee joint system as a new tool to study the role of neuro-immune interactions in osteoarthritis pain. The University of Pittsburgh, the awardee, will use this novel microphysiological system with cartilage,...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is providing $1,958,125.00 to the University of Oregon to develop an innovative nanoparticle drug delivery system to improve tendon regeneration following acute injuries. The researchers aim to leverage a novel peptide that specifically targets and binds to inflammation markers in healing...
- The federal Project Grant award of $426,889.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the molecular regulatory mechanisms of a cartilage-enriched G-protein coupled receptor (GPCR) named ADGRG6 and its role in maintaining joint and cartilage homeostasis. The project, awarded to the University of Southern California, aims to investigate the...
- This federal Project Grant award of $570,174 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports the development and evaluation of a zonal-specific mineralized scaffold optimal for osteochondral (OC) tissue regeneration. The research aims to mimic the hierarchical microstructure and composition of native OC tissue, which consists of articular cartilage and subchondral...
- This $361,300 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) will support research to identify new cell signaling pathways and therapeutic targets for disease modification in osteoarthritis (OA). The University of North Carolina at Chapel Hill will conduct high-throughput screening of small molecules to discover signaling pathways...
- This Project Grant award of $434,682 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of the award is to precisely define the proteolytic events and mechanisms along the timeline of post-traumatic osteoarthritis (PTOA), leveraging a specialized proteomics approach called "degradomics." The award recipient, the Cleveland Clinic...
- This $297,327 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports Navega Therapeutics, Inc. in reformulating their NT-Z001 gene therapy to treat rheumatoid arthritis. The goal is to enable localized joint injections instead of the more invasive intrathecal delivery route. NT-Z001 targets the NAV1.7 sodium channel, a key mediator of pain, with the...
- This $426,250 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to the Regents of the University of Minnesota aims to develop an exosome-based therapy for the treatment of osteoarthritis (OA). The project will leverage the immunoregulatory mechanisms present during fetal development to identify multi-tissue organoid-derived exosomes with anti-inflammatory and chondrocyte proliferation potential. Key activities include in vitro studies using human PBMCs to...